Rivo Bio is developing the next generation of neuromedicines with a proprietary computationally enabled approach to rational multi-target drug design, modernizing drug discovery for complex neurodisorders. Supported by advances in AI technology, we design single drugs with intentional multimodal activity to achieve greater efficacy and safety in hard-to-treat diseases.
We are focusing on developing multifunctional small molecule therapeutics for treating central nervous system disorders, including:
Neuropsychiatric Disorders
Neurological Disorders
Neurodegenerative Diseases
We have demonstrated early traction in:
R&D Pipeline: Identification of unique target modules and design, synthesis, and in vitro characterization of novel compounds for the treatment of central nervous system disorders, with lead program in lead optimization.
Intellectual Property Milestones: Fast-tracked US and international patent applications filed in January 2025 to cover the composition of matter for multiple chemotypes comprising thousands of compounds.
Proprietary Discovery Technology: Development of innovative and proprietary models for design of multi-target ligands for improved efficacy and safety of next-gen therapeutics.
Multi-target drug design: one drug modulating multiple protein targets/pathways for maximum therapeutic efficacy.
Please email for collaboration or investment inquiry.